Can Immunotherapy in HER2+ Breast Cancer Suppress Trastuzumab Resistance? – Cancer Network
OncLive |
Can Immunotherapy in HER2+ Breast Cancer Suppress Trastuzumab Resistance?
Cancer Network The combination of pembrolizumab and trastuzumab showed promising clinical benefit in patients with trastuzumab-resistant HER2-positive advanced breast cancer who express PD-L1, according to a new study. “We believe that immune evasion is part of the … Alpine Immune Sciences Announces Preclinical Data Showing Novel Immuno-Oncology Costimulatory Molecules … Pembrolizumab combination shows early potential for trastuzumab-resistant breast cancer |
